Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer

NorthShore University HealthSystem

Status and phase: Completed; Phase 2

Conditions: Prostate Cancer

Treatments: Drug: Dutasteride; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT00668642

EH07-109

Details and patient eligibility

About

The purpose of this study is to determine if the drug dutasteride increases expression of genes that slow the growth of prostate cancer during treatment with intermittent androgen ablation therapy (hormone therapy).

Full description

We have shown in a murine model of treatment with intermittent androgen ablation therapy of prostate cancer that when dutasteride is given during the regrowth phase (off-phase) of intermittent therapy, that tumor growth is inhibited and that survival is improved. We have also shown that testosterone is a more potent inducer of certain tumor suppressor androgen response genes than dihydrotestosterone. In this murine model, we showed that use of a 5-alpha reductase inhibitor (dutasteride) resulted in significant hyperinduction of the U19 tumor suppressor androgen response gene during the regrowth phase of treatment. In the current clinical trial, we will determine if use of dutasteride in men with advanced prostate cancer during the off-phase of intermittent androgen ablation therapy will also result in hyperinduction of these tumor suppressor androgen response genes. Gene expression will be measured in tumor tissue obtained by prostate biopsies during the off-phase when the testosterone level has normalized. Prostate-specific antigen (PSA) levels will also be measured to determine the PSA doubling time during the off-phase to determine the effect of dutasteride on PSA kinetics.

Enrollment: 20 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically proven prostate cancer
• Patients are hormone-naive
• Patients either to begin androgen ablation therapy with luteinizing hormone-releasing hormone (LHRH) agonist or already receiving therapy with LHRH agonist
• Advanced prostate cancer with either positive pelvic nodes or bone/visceral metastasis
• Must have an intact prostate (no previous surgery or XRT)
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• Recovery from any major infection or surgical procedure
• Signed informed consent

Exclusion criteria

• Known intolerance or allergy to dutasteride
• Concomitant chemotherapy, biologic therapy, or XRT to prostate
• Bilateral orchiectomy
• Prior malignancy within 5 years of registration

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

20 participants in 2 patient groups, including a placebo group

A: Dutasteride During First Off-Cycle

Experimental group

Description:

Arm A patients received dutasteride (0.5 mg/day) during the first off-cycle and received placebo during the second off-cycle

Treatment:

Drug: Dutasteride

B: Placebo During First Off-Cycle

Placebo Comparator group

Description:

Arm B patients received placebo during the first off-cycle and received dutasteride (0.5 mg/day) during the second off-cycle

Treatment:

Drug: Placebo